9 Einträge gefunden

1. Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial

   1. Stein, Alexander
   2. Paschold, Lisa
   3. Tintelnot, Joseph
   4. Goekkurt, Eray
   5. Henkes, Svenja-Sibylla
   6. Simnica, Donjete
   7. Schultheiss, Christoph

   2022 - Forschungsinformationssystem des UKE
2. Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer

   1. Tintelnot, Joseph
   2. Ristow, Inka
   3. Sauer, Markus
   4. Simnica, Donjete
   5. Schultheiß, Christoph
   6. Scholz, Rebekka
   7. Goekkurt, Eray

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice

   1. Reinacher-Schick, Anke
   2. Arnold, Dirk
   3. Venerito, Marino
   4. Goekkurt, Eray
   5. Kraeft, Anna-Lena
   6. Seufferlein, Thomas

   2022 - Forschungsinformationssystem des UKE
4. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)

   1. Modest, Dominik Paul
   2. Karthaus, Meinolf
   3. Fruehauf, Stefan
   4. Graeven, Ullrich
   5. Müller, Lothar
   6. König, Alexander Otto
   7. Fischer von Weikersthal, Ludwig

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
5. FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group

   1. Hofheinz, Ralf-Dieter
   2. Merx, Kirsten
   3. Haag, Georg M
   4. Springfeld, Christoph
   5. Ettrich, Thomas
   6. Borchert, Kersten
   7. Kretzschmar, Albrecht

   2022 - Forschungsinformationssystem des UKE
6. Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report

   1. Velthaus, Janna-Lisa
   2. Iglauer, Peter
   3. Simon, Ronald
   4. Bokemeyer, Carsten
   5. Bannas, Peter
   6. Beumer, Niklas
   7. Imbusch, Charles D

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
7. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)

   1. Tintelnot, Joseph
   2. Goekkurt, Eray
   3. Binder, Mascha
   4. Thuss-Patience, Peter
   5. Lorenzen, Sylvie
   6. Knorrenschild, Jorge Riera
   7. Kretzschmar, Albrecht

   2020 - Forschungsinformationssystem des UKE
8. T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker

   1. Akyüz, Nuray
   2. Brandt, Anna
   3. Stein, Alexander
   4. Schliffke, Simon
   5. Mährle, T
   6. Quidde, Julia
   7. Goekkurt, Eray

   2017 - Forschungsinformationssystem des UKE
9. Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity

   1. Harbaum, Lars
   2. Marx, Andreas
   3. Goekkurt, Eray
   4. Schafhausen, Philippe
   5. Atanackovic, Djordje

   2014 - Forschungsinformationssystem des UKE